Developer docs
API playgroundTry for free, no card

Search company profiles

Sylics

Full company profile

uuid002mxtj

Namestring
Sylics
Legal namestring
InnoSer
Websiteurl
sylics.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Sylics is the pre-2020 identity of what now operates as InnoSer, a privately held European preclinical Contract Research Organization headquartered in Bilthoven, Netherlands, with a website that redirects from sylics.com to innoserlaboratories.com. The legal entity operates as InnoSer and serves a stated base of more than 200 pharmaceutical and biotechnology customers, including named accounts such as Roche, AstraZeneca, Daiichi Sankyo, Bayer, Bial, Agomab, Carthera, Upyther, and Montis. The company is small (11-50 employees) and privately funded, with no disclosed revenue, funding rounds, or investor information.

InnoSer's core offering is an integrated preclinical services platform covering the full discovery-to-preclinical arc: target validation, hit-to-lead, lead optimization, and preclinical drug development. Capabilities include validated in vivo mouse and rat disease models, rodent behavioral testing, histopathology and bioanalysis, colony management, and vivarium facility rental. The therapeutic footprint spans neurology (Alzheimer's, Parkinson's, ALS, Huntington's, multiple sclerosis, spinal cord injury), oncology (syngeneic, CDX, PDX, humanized, and organoid high-throughput screening models), immunology (autoimmune, inflammatory, vaccine/mRNA testing), nephrology (including the P40 adult-onset ADPKD model with longitudinal ultrasound TKV), cardiovascular (TAC, hypertension, diabetic cardiomyopathy), metabolic disease, and a deep rare disease catalog (Fragile X, Angelman, STXBP1, CMT1A, Kabuki, Phelan-McDermid, 22q11.2, and others). Differentiated technical assets include plasma and tissue biomarker panels (amyloid-beta, phosphorylated Tau, neurofilament light) and an ultrasound-mediated blood-brain barrier delivery (Sonocloud) model.

The business model is fee-for-service preclinical CRO work with custom per-study quotes, transparent upfront pricing, and multi-year contract potential. Go-to-market is sales-led and consultative, using 'Free Consultation' and 'Contact an Expert' CTAs, scientist-to-scientist engagement, dedicated study management, scientific content marketing via therapeutic-area newsletters, and conference presence. AAALAC International accreditation and a 3R's policy support regulatory and journal-publication credibility. The company maintains a Scientific Board for external scientific oversight and targets primary customer segments of Big Pharma and biotech firms needing AAALAC-accredited, customized preclinical execution across multiple therapeutic areas.

Short descriptiontext

Sylics, now operating as InnoSer, is a Netherlands-based preclinical contract research organization serving 200+ pharma and biotech clients with integrated in vivo disease models, behavioral testing, pathology, and bioanalysis across neurology, oncology, immunology, cardiovascular, metabolic, and rare disease programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBilthoven, Netherlands
HQ citystring
Bilthoven
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
preclinical CRO services, drug discovery research, animal model research, translational neuroscience, contract research organization
Industry2 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical Contract Research Services
TypeProfessional Services
Description

Fee-for-service preclinical CRO engagements covering study design, execution, and data delivery across in vivo models, in vitro assays, pathology, and bioanalysis. Revenue is generated on a per-study or milestone basis with pricing described as transparent and upfront. Engagements span from discovery through preclinical development phases.

innoserlaboratories.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom study pricing — quote-based
ModelOtherBilling cadenceMulti-year contract
Notes

Study-specific pricing; no public tier list. 'Free Consultation' and 'Contact an Expert' CTAs indicate a consultative sales process with custom quotes per study.

innoserlaboratories.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sylics (operating as InnoSer) is a European preclinical Contract Research Organization (CRO) providing fee-for-service drug discovery and preclinical development services. The company delivers in vivo and in vitro research using validated mouse and rodent models across therapeutic areas including neurology, oncology, immunology, nephrology, cardiovascular, metabolic, and rare diseases, with AAALAC-accredited vivarium facilities, pathology, behavioral testing, colony management, and biomarker capabilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 200+ pharmaceutical and biotech companies served
Product overview1 text field

InnoSer is a European preclinical Contract Research Organization (CRO) offering a comprehensive portfolio of drug discovery and development services. The company provides an integrated service platform spanning from target validation through preclinical development, utilizing validated animal models across multiple therapeutic areas including neurology, oncology, immunology, nephrology, cardiovascular, metabolic, and rare diseases. Services include in vivo models, behavioral testing, pathology, colony management, and facility rental, supported by dedicated study management and scientist-to-scientist collaboration.

Product and service16 records
1In Vivo Models
CategoryPreclinical Research Service
Description

Mouse and rodent models for preclinical research across multiple therapeutic areas including oncology, neurology, immunology, and rare diseases, offered to pharmaceutical and biotech clients.

2Rodent Behavioral Testing
CategoryPreclinical Research Service
Description

Behavioral testing services for neurology research models assessing cognitive and motor function in rodents, used by pharma and biotech researchers.

3Pathology Services
CategoryPreclinical Research Service
Description

Histopathology, immunohistochemistry, and tissue analysis services supporting preclinical drug development for pharmaceutical and biotech clients.

4Colony Management
CategoryPreclinical Research Service
Description

Breeding, genetic validation, and cryopreservation services for genetically modified animal models, provided to preclinical research clients.

5Facility Management
CategoryPreclinical Research Service
Description

Vivarium rental and facility management solutions for preclinical research operations, available to pharmaceutical and biotech organizations.

6Target Validation
CategoryPreclinical Research Service
Description

Early discovery phase services identifying and validating novel therapeutic candidates using validated disease models for pharma and biotech clients.

7Hit-to-Lead
CategoryPreclinical Research Service
Description

In vitro screening and mechanism-of-action studies evaluating compound efficacy and cytotoxicity during early drug discovery for pharmaceutical clients.

8Lead Optimization
CategoryPreclinical Research Service
Description

PK/PD assessments and non-GLP toxicity profiling to prepare drug candidates for regulatory preclinical studies, targeting pharma R&D teams.

9Preclinical Drug Development Services
CategoryPreclinical Research Service
Description

Late-stage non-GLP preclinical studies including efficacy testing, dosing strategy refinement, and combination therapy studies for pharmaceutical and biotech sponsors.

10Neurology CRO Services
CategoryTherapeutic Area Service
Description

Integrated neurology research services spanning in vitro to in vivo research, including Alzheimer's, Parkinson's, ALS, Huntington's, and Multiple Sclerosis models.

11Oncology CRO Services
CategoryTherapeutic Area Service
Description

Comprehensive oncology services including syngeneic models, xenografts, organoid screening, and patient-derived xenografts for oncology drug development.

12Immunology CRO Services
CategoryTherapeutic Area Service
Description

In vitro and in vivo immunology models for hypersensitivity, inflammatory, and autoimmune diseases including vaccine testing for pharmaceutical sponsors.

13Cardiovascular CRO Services
CategoryTherapeutic Area Service
Description

Mouse models for cardiovascular diseases and heart failure (HFrEF and HFpEF) with cardiac surgery and technical procedures for cardiovascular drug discovery.

14Metabolic Disease CRO Services
CategoryTherapeutic Area Service
Description

Gold-standard mouse models for obesity, type 2 diabetes, and associated complications including cardiac dysfunction for metabolic drug research.

15Nephrology CRO Services
CategoryTherapeutic Area Service
Description

Kidney disease research services including ADPKD models with ultrasound-based total kidney volume assessments for renal drug development programs.

16Rare Disease Research Models
CategoryTherapeutic Area Service
Description

Preclinical models for rare diseases including Fragile X Syndrome, Vanishing White Matter, Angelman Syndrome, Tuberous Sclerosis, and other rare neurological conditions.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Scientific Board (InnoSer)
Strategic tierCoreTypeOthers
Description

InnoSer maintains a Scientific Board comprising recognized scientific experts who provide strategic guidance and oversight for the company's research portfolio and model development, lending credibility and scientific rigor to the CRO services.

innoserlaboratories.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Roche is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services. No further detail on the scope of engagement is provided.

Strategic tierMinorTypeGTM or Marketing Partner
Description

AstraZeneca is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Daiichi Sankyo is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Bayer is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Bial is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Agomab is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Carthera is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services, potentially leveraging InnoSer's ultrasound-mediated BBB drug delivery model.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Upyther is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Montis is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

NIN is listed among InnoSer's customer/partner logos, suggesting a collaboration in neuroscience preclinical research.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Regel is listed among InnoSer's biotech/pharma customers or partners.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Illimis is listed among InnoSer's biotech/pharma customers or partners.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Part of Eurofins Group, this discovery services arm offers in vitro pharmacology, ADME, and in vivo services that overlap with InnoSer's preclinical testing capabilities across multiple therapeutic areas.

TypeBroad incumbent
Description

Integrated CRO/CDMO offering discovery, preclinical, and clinical services across multiple therapeutic areas, providing similar full preclinical value chain services to large pharma clients.

TypeBroad incumbent
Description

Global preclinical and clinical CRO offering end-to-end discovery, safety, and manufacturing services including the RMS (Research Models and Services) segment that directly overlaps with InnoSer's in vivo model and preclinical offerings.

TypeDirect peer
Description

Discovery and preclinical CRO with integrated medicinal chemistry, in vitro, and in vivo pharmacology capabilities serving similar biotech and pharma clients, especially in CNS and inflammation.

TypeDirect peer
Description

Preclinical CRO specializing in CNS/neurology rodent models, behavioral phenotyping, and drug discovery — directly comparable to InnoSer's neurology research models and behavioral testing services portfolio.

TypeDirect peer
Description

Oncology-focused preclinical CRO with extensive syngeneic, xenograft, PDX, and humanized model portfolios that overlap directly with InnoSer's oncology CRO services and organoid screening capabilities.

TypeDirect peer
Description

Global CRO with strong preclinical and translational pharmacology services in CNS, metabolic, and rare disease areas, providing similar in vivo DMPK and efficacy study offerings to pharma and biotech.

TypeEmerging player
Description

Preclinical CRO and gene-editing specialist offering humanized mouse models and translational in vivo efficacy services, partially overlapping with InnoSer's humanized mouse and oncology offerings.

9Labcorp (Covance)
TypeBroad incumbent
Description

Diversified CRO with a leading preclinical and central laboratory services franchise spanning discovery through clinical development, competing head-to-head with specialist preclinical CROs on integrated study designs.

TypeBroad incumbent
Description

Asia-headquartered full-service CRO with significant preclinical, DMPK, and safety assessment capacity — competes with InnoSer in global pharma RFPs for integrated preclinical packages and translational biomarker studies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sylics

Preclinical Contract Research Servicessylics.com

Sylics, now operating as InnoSer, is a Netherlands-based preclinical contract research organization serving 200+ pharma and biotech clients with integrated in vivo disease models, behavioral testing, pathology, and bioanalysis across neurology, oncology, immunology, cardiovascular, metabolic, and rare disease programs.

What Sylics does

Sylics is the pre-2020 identity of what now operates as InnoSer, a privately held European preclinical Contract Research Organization headquartered in Bilthoven, Netherlands, with a website that redirects from sylics.com to innoserlaboratories.com. The legal entity operates as InnoSer and serves a stated base of more than 200 pharmaceutical and biotechnology customers, including named accounts such as Roche, AstraZeneca, Daiichi Sankyo, Bayer, Bial, Agomab, Carthera, Upyther, and Montis. The company is small (11-50 employees) and privately funded, with no disclosed revenue, funding rounds, or investor information.

InnoSer's core offering is an integrated preclinical services platform covering the full discovery-to-preclinical arc: target validation, hit-to-lead, lead optimization, and preclinical drug development. Capabilities include validated in vivo mouse and rat disease models, rodent behavioral testing, histopathology and bioanalysis, colony management, and vivarium facility rental. The therapeutic footprint spans neurology (Alzheimer's, Parkinson's, ALS, Huntington's, multiple sclerosis, spinal cord injury), oncology (syngeneic, CDX, PDX, humanized, and organoid high-throughput screening models), immunology (autoimmune, inflammatory, vaccine/mRNA testing), nephrology (including the P40 adult-onset ADPKD model with longitudinal ultrasound TKV), cardiovascular (TAC, hypertension, diabetic cardiomyopathy), metabolic disease, and a deep rare disease catalog (Fragile X, Angelman, STXBP1, CMT1A, Kabuki, Phelan-McDermid, 22q11.2, and others). Differentiated technical assets include plasma and tissue biomarker panels (amyloid-beta, phosphorylated Tau, neurofilament light) and an ultrasound-mediated blood-brain barrier delivery (Sonocloud) model.

The business model is fee-for-service preclinical CRO work with custom per-study quotes, transparent upfront pricing, and multi-year contract potential. Go-to-market is sales-led and consultative, using 'Free Consultation' and 'Contact an Expert' CTAs, scientist-to-scientist engagement, dedicated study management, scientific content marketing via therapeutic-area newsletters, and conference presence. AAALAC International accreditation and a 3R's policy support regulatory and journal-publication credibility. The company maintains a Scientific Board for external scientific oversight and targets primary customer segments of Big Pharma and biotech firms needing AAALAC-accredited, customized preclinical execution across multiple therapeutic areas.

Sylics firmographics

Firmographics
Name
Sylics
Legal name
InnoSer
Website
https://sylics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Sylics, now operating as InnoSer, is a Netherlands-based preclinical contract research organization serving 200+ pharma and biotech clients with integrated in vivo disease models, behavioral testing, pathology, and bioanalysis across neurology, oncology, immunology, cardiovascular, metabolic, and rare disease programs.
Ownership category
akta.pro rank

Sylics industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Preclinical CRO services
  • Drug discovery research
  • Animal model research
  • Translational neuroscience
  • Contract research organization

Where Sylics is headquartered

Location

Headquarters

HQ city
Bilthoven
HQ country
Netherlands
HQ region
Europe

Markets served

Sylics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Preclinical Contract Research Services: Fee-for-service preclinical CRO engagements covering study design, execution, and data delivery across in vivo models, in vitro assays, pathology, and bioanalysis. Revenue is generated on a per-study or milestone basis with pricing described as transparent and upfront. Engagements span from discovery through preclinical development phases.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom study pricing — quote-based

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Sylics product offering

Product offering

Core offering

Sylics (operating as InnoSer) is a European preclinical Contract Research Organization (CRO) providing fee-for-service drug discovery and preclinical development services. The company delivers in vivo and in vitro research using validated mouse and rodent models across therapeutic areas including neurology, oncology, immunology, nephrology, cardiovascular, metabolic, and rare diseases, with AAALAC-accredited vivarium facilities, pathology, behavioral testing, colony management, and biomarker capabilities.

Product overview

InnoSer is a European preclinical Contract Research Organization (CRO) offering a comprehensive portfolio of drug discovery and development services. The company provides an integrated service platform spanning from target validation through preclinical development, utilizing validated animal models across multiple therapeutic areas including neurology, oncology, immunology, nephrology, cardiovascular, metabolic, and rare diseases. Services include in vivo models, behavioral testing, pathology, colony management, and facility rental, supported by dedicated study management and scientist-to-scientist collaboration.

Differentiator

Problem solved

Functional benefit

Products and services

  • In Vivo Models Mouse and rodent models for preclinical research across multiple therapeutic areas including oncology, neurology, immunology, and rare diseases, offered to pharmaceutical and biotech clients.
  • Rodent Behavioral Testing Behavioral testing services for neurology research models assessing cognitive and motor function in rodents, used by pharma and biotech researchers.
  • Pathology Services Histopathology, immunohistochemistry, and tissue analysis services supporting preclinical drug development for pharmaceutical and biotech clients.
  • Colony Management Breeding, genetic validation, and cryopreservation services for genetically modified animal models, provided to preclinical research clients.
  • Facility Management Vivarium rental and facility management solutions for preclinical research operations, available to pharmaceutical and biotech organizations.
  • Target Validation Early discovery phase services identifying and validating novel therapeutic candidates using validated disease models for pharma and biotech clients.
  • Hit-to-Lead In vitro screening and mechanism-of-action studies evaluating compound efficacy and cytotoxicity during early drug discovery for pharmaceutical clients.
  • Lead Optimization PK/PD assessments and non-GLP toxicity profiling to prepare drug candidates for regulatory preclinical studies, targeting pharma R&D teams.
  • Preclinical Drug Development Services Late-stage non-GLP preclinical studies including efficacy testing, dosing strategy refinement, and combination therapy studies for pharmaceutical and biotech sponsors.
  • Neurology CRO Services Integrated neurology research services spanning in vitro to in vivo research, including Alzheimer's, Parkinson's, ALS, Huntington's, and Multiple Sclerosis models.
  • Oncology CRO Services Comprehensive oncology services including syngeneic models, xenografts, organoid screening, and patient-derived xenografts for oncology drug development.
  • Immunology CRO Services In vitro and in vivo immunology models for hypersensitivity, inflammatory, and autoimmune diseases including vaccine testing for pharmaceutical sponsors.
  • Cardiovascular CRO Services Mouse models for cardiovascular diseases and heart failure (HFrEF and HFpEF) with cardiac surgery and technical procedures for cardiovascular drug discovery.
  • Metabolic Disease CRO Services Gold-standard mouse models for obesity, type 2 diabetes, and associated complications including cardiac dysfunction for metabolic drug research.
  • Nephrology CRO Services Kidney disease research services including ADPKD models with ultrasound-based total kidney volume assessments for renal drug development programs.
  • Rare Disease Research Models Preclinical models for rare diseases including Fragile X Syndrome, Vanishing White Matter, Angelman Syndrome, Tuberous Sclerosis, and other rare neurological conditions.

Quantifiable outcome

  • 200+ pharmaceutical and biotech companies served

Companies that use Sylics

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Sylics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Sylics partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Scientific Board (InnoSer)coreOthersInnoSer maintains a Scientific Board comprising recognized scientific experts who provide strategic guidance and oversight for the company's research portfolio and model development, lending credibility and scientific rigor to the CRO services.
  • RocheminorGTM or Marketing PartnerRoche is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services. No further detail on the scope of engagement is provided.
  • AstraZenecaminorGTM or Marketing PartnerAstraZeneca is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.
  • Daiichi SankyominorGTM or Marketing PartnerDaiichi Sankyo is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.
  • BayerminorGTM or Marketing PartnerBayer is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.
  • BialminorGTM or Marketing PartnerBial is listed among InnoSer's 200+ pharmaceutical and biotech customers, indicating a vendor-customer relationship for preclinical research services.
  • AgomabminorGTM or Marketing PartnerAgomab is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services.
  • CartheraminorGTM or Marketing PartnerCarthera is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services, potentially leveraging InnoSer's ultrasound-mediated BBB drug delivery model.
  • UpytherminorGTM or Marketing PartnerUpyther is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services.
  • MontisminorGTM or Marketing PartnerMontis is listed among InnoSer's biotech customers, indicating a vendor-customer relationship for preclinical research services.
  • NIN (Netherlands Institute for Neuroscience)minorStrategic or Co-development PartnerNIN is listed among InnoSer's customer/partner logos, suggesting a collaboration in neuroscience preclinical research.
  • RegelminorGTM or Marketing PartnerRegel is listed among InnoSer's biotech/pharma customers or partners.
  • IllimisminorGTM or Marketing PartnerIllimis is listed among InnoSer's biotech/pharma customers or partners.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Sylics competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Discovery: Part of Eurofins Group, this discovery services arm offers in vitro pharmacology, ADME, and in vivo services that overlap with InnoSer's preclinical testing capabilities across multiple therapeutic areas.
  • Pharmaron: Integrated CRO/CDMO offering discovery, preclinical, and clinical services across multiple therapeutic areas, providing similar full preclinical value chain services to large pharma clients.
  • Charles River Laboratories: Global preclinical and clinical CRO offering end-to-end discovery, safety, and manufacturing services including the RMS (Research Models and Services) segment that directly overlaps with InnoSer's in vivo model and preclinical offerings.
  • Labcorp (Covance): Diversified CRO with a leading preclinical and central laboratory services franchise spanning discovery through clinical development, competing head-to-head with specialist preclinical CROs on integrated study designs.
  • Wuxi AppTec: Asia-headquartered full-service CRO with significant preclinical, DMPK, and safety assessment capacity — competes with InnoSer in global pharma RFPs for integrated preclinical packages and translational biomarker studies.

Direct peers

  • Sygnature Discovery: Discovery and preclinical CRO with integrated medicinal chemistry, in vitro, and in vivo pharmacology capabilities serving similar biotech and pharma clients, especially in CNS and inflammation.
  • PsychoGenics: Preclinical CRO specializing in CNS/neurology rodent models, behavioral phenotyping, and drug discovery — directly comparable to InnoSer's neurology research models and behavioral testing services portfolio.
  • Crown Bioscience: Oncology-focused preclinical CRO with extensive syngeneic, xenograft, PDX, and humanized model portfolios that overlap directly with InnoSer's oncology CRO services and organoid screening capabilities.
  • QPS Holdings: Global CRO with strong preclinical and translational pharmacology services in CNS, metabolic, and rare disease areas, providing similar in vivo DMPK and efficacy study offerings to pharma and biotech.

Emerging players

  • Biocytogen: Preclinical CRO and gene-editing specialist offering humanized mouse models and translational in vivo efficacy services, partially overlapping with InnoSer's humanized mouse and oncology offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sylics social profiles

Digital presence

Sylics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sylics leadership team

Management profile

Number of profiles

Sylics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sylics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sylics

What does Sylics do?

Sylics (operating as InnoSer) is a European preclinical Contract Research Organization (CRO) providing fee-for-service drug discovery and preclinical development services. The company delivers in vivo and in vitro research using validated mouse and rodent models across therapeutic areas including neurology, oncology, immunology, nephrology, cardiovascular, metabolic, and rare diseases, with AAALAC-accredited vivarium facilities, pathology, behavioral testing, colony management, and biomarker capabilities.

Is Sylics a public or private company?

Sylics is a private company. It is classified as unknown and is currently operating.

When was Sylics founded?

Sylics was founded in 2020. It employs 1 to 10 people.

Where is Sylics based?

Sylics is headquartered in Bilthoven, Netherlands, in the Europe region.

How does Sylics make money?

One revenue line is on record: preclinical Contract Research Services.

Who are Sylics's main competitors?

Broad incumbents on record are Eurofins Discovery, Pharmaron, Charles River Laboratories, Labcorp (Covance) and Wuxi AppTec. Direct peers are Sygnature Discovery, PsychoGenics, Crown Bioscience and QPS Holdings. Biocytogen is listed as an emerging player.

Does Sylics have an API?

No public API is recorded for Sylics.

What industry is Sylics in?

Sylics's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54169 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales